Milena Sullivan

Milena Sullivan advises life sciences clients on the impact of the evolving healthcare policy landscape on their commercial, access, and advocacy priorities.

She focuses on federal health policy in government-regulated markets such as Medicare policy and payment as well as on state policy advocacy and strategy.

Prior to re-joining Avalere, Milena was associate director for Oncology Policy, Market Access, at Bristol-Myers Squibb, where she identified, analyzed, and communicated policy risks and opportunities impacting the oncology business unit, its patients, and customers. She identified competitive opportunities for the company under new CMS payment models and educated internal teams on the evolving public payer landscape. Prior to that, she was a senior manager at Avalere Health, where she supported life science clients on various policy and strategy issues and managed engagements with vaccine companies. She was a project manager, Government Affairs and Public Policy, at Novartis, where she analyzed the impact of the ACA on the vaccine division’s products and customers and led trainings for field-based staff.

Milena has an MA in international policy and practice from The George Washington University and a BA from Miami University of Ohio.

Authored Content

Avalere analysis finds that 24 of the top 50 non-vaccine Part B drugs are not on the U.S. Department of Veterans Affairs’ National Formulary.

Avalere analysis of 1,375 Medicare Advantage plans’ 2019 medical benefit drug coverage policies finds that 672—covering approximately 14.3 million lives—apply step therapy to at least 1 of the rheumatoid arthritis biologic drugs covered under Medicare Part B in 2019.

As policymakers explore opportunities to reform Medicare Part B, a tiered average sales price (ASP) add-on payment may be under consideration to align system incentives and curb spending.

Ahead of the American Society of Clinical Oncology's annual meeting, Avalere experts discussed the latest trends in policy, reimbursement, and market access reshaping oncology care.

The costs of ensuring the safety and efficacy of imported drugs and preventing the entry of counterfeit products are among the many factors that must be weighed against any potential savings from a drug importation program.

New Avalere analysis finds that most seniors in Medicare would not see a reduction in their out-of-pocket costs as a result of the International Price Index Model.

Avalere analysis finds that most of the payment reductions from the proposed International Pricing Index Model for Part B drugs would affect oncologists, rheumatologists, and ophthalmologists.

Avalere experts examine the current drug pricing policy landscape and what potential changes stakeholders should prepare for.

New research from Avalere finds that Medicare patients with rheumatoid arthritis (RA) may face higher out-of-pocket costs under a proposal to move Medicare Part B drugs into Part D, absent additional policy change to lower cost sharing in the Part D program.

Under an indication-based formulary design approach, Part D plans will be able to tailor the drugs that are on their formulary by indication.

Beginning in January 2019, Medicare Advantage (MA) plans will have the flexibility to use step-therapy techniques for Part B drugs, according to a CMS memo released on August 7.

A proposed shift of Part B drugs into Part D could affect patient access and increase the burden on providers.

The Department of Health and Human Services is seeking public input on a variety of proposals related to drug costs, providing stakeholders with an unprecedented opportunity to shape the administration's drug pricing policies.

President Trump is expected to announce a drug pricing plan in the coming weeks; signals from the White House indicate potential alignment around several priority policies.

As the discussion intensifies, one of Avalere's experts provides keen observations on what you need to know about this topic.